Conexeu Sciences Inc. Common Stock (CNXU) is a publicly traded the market company. As of July 7, 2026, CNXU trades at $9.32 with a market cap of $290.60M and a P/E ratio of 0.00. CNXU moved -12.78% today. Year to date, CNXU is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $9.60 to $18.79. Analyst consensus is buy with an average price target of $20.00. Rallies surfaces CNXU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Conexeu Completes P.R.O.O.F Phase, Targets $11B Injectables Market: Conexeu completed the P.R.O.O.F phase of its CXU preclinical program, validating facial, body and mechanical performance objectives for its tissue-restoration platform. The company targets an $11B injectables market and plans a predicate-based 510(k) filing in Q1 2027 to tap a $0.7B-$2B provider economy by 2030.
| Metric | Value |
|---|---|
| Price | $9.32 |
| Market Cap | $290.60M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.79 |
| 52-Week Low | $9.60 |
| Volume | 304.85K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover CNXU: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.00.